PMC:7228307 / 52708-52886 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1063","span":{"begin":62,"end":67},"obj":"Gene"},{"id":"1069","span":{"begin":45,"end":55},"obj":"Chemical"},{"id":"1070","span":{"begin":73,"end":84},"obj":"Chemical"},{"id":"1071","span":{"begin":171,"end":176},"obj":"Mutation"}],"attributes":[{"id":"A1063","pred":"tao:has_database_id","subj":"1063","obj":"Gene:29126"},{"id":"A1069","pred":"tao:has_database_id","subj":"1069","obj":"MESH:C000613593"},{"id":"A1070","pred":"tao:has_database_id","subj":"1070","obj":"MESH:C582345"},{"id":"A1071","pred":"tao:has_standard_notation","subj":"1071","obj":"p.L234F"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The lower hinge amino acids of the IgG1 mAbs durvalumab (anti‐PD‐L1) and anifrolumab (anti‐interferon‐α receptor; Table 4) were modified to mimic the lower hinge of IgG4 (L234F)."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T408","span":{"begin":16,"end":27},"obj":"Body_part"}],"attributes":[{"id":"A408","pred":"fma_id","subj":"T408","obj":"http://purl.org/sig/ont/fma/fma82739"}],"text":"The lower hinge amino acids of the IgG1 mAbs durvalumab (anti‐PD‐L1) and anifrolumab (anti‐interferon‐α receptor; Table 4) were modified to mimic the lower hinge of IgG4 (L234F)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T892","span":{"begin":62,"end":67},"obj":"http://purl.obolibrary.org/obo/CLO_0008407"}],"text":"The lower hinge amino acids of the IgG1 mAbs durvalumab (anti‐PD‐L1) and anifrolumab (anti‐interferon‐α receptor; Table 4) were modified to mimic the lower hinge of IgG4 (L234F)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T10443","span":{"begin":16,"end":27},"obj":"Chemical"},{"id":"T57589","span":{"begin":16,"end":21},"obj":"Chemical"},{"id":"T8912","span":{"begin":22,"end":27},"obj":"Chemical"},{"id":"T75315","span":{"begin":62,"end":64},"obj":"Chemical"},{"id":"T36188","span":{"begin":91,"end":101},"obj":"Chemical"}],"attributes":[{"id":"A72620","pred":"chebi_id","subj":"T10443","obj":"http://purl.obolibrary.org/obo/CHEBI_33709"},{"id":"A36706","pred":"chebi_id","subj":"T57589","obj":"http://purl.obolibrary.org/obo/CHEBI_46882"},{"id":"A23112","pred":"chebi_id","subj":"T8912","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A81916","pred":"chebi_id","subj":"T75315","obj":"http://purl.obolibrary.org/obo/CHEBI_74756"},{"id":"A4305","pred":"chebi_id","subj":"T36188","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"}],"text":"The lower hinge amino acids of the IgG1 mAbs durvalumab (anti‐PD‐L1) and anifrolumab (anti‐interferon‐α receptor; Table 4) were modified to mimic the lower hinge of IgG4 (L234F)."}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T58","span":{"begin":16,"end":27},"obj":"Chemical"}],"attributes":[{"id":"A58","pred":"chebi_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/CHEBI_33709"}],"text":"The lower hinge amino acids of the IgG1 mAbs durvalumab (anti‐PD‐L1) and anifrolumab (anti‐interferon‐α receptor; Table 4) were modified to mimic the lower hinge of IgG4 (L234F)."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"1063","span":{"begin":62,"end":67},"obj":"Gene"},{"id":"1069","span":{"begin":45,"end":55},"obj":"Chemical"},{"id":"1070","span":{"begin":73,"end":84},"obj":"Chemical"},{"id":"1071","span":{"begin":171,"end":176},"obj":"Mutation"}],"attributes":[{"id":"A1063","pred":"pubann:denotes","subj":"1063","obj":"Gene:29126"},{"id":"A1069","pred":"pubann:denotes","subj":"1069","obj":"MESH:C000613593"},{"id":"A1070","pred":"pubann:denotes","subj":"1070","obj":"MESH:C582345"},{"id":"A1071","pred":"pubann:has_HGVS_notation","subj":"1071","obj":"p.L234F"}],"text":"The lower hinge amino acids of the IgG1 mAbs durvalumab (anti‐PD‐L1) and anifrolumab (anti‐interferon‐α receptor; Table 4) were modified to mimic the lower hinge of IgG4 (L234F)."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T300","span":{"begin":0,"end":178},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The lower hinge amino acids of the IgG1 mAbs durvalumab (anti‐PD‐L1) and anifrolumab (anti‐interferon‐α receptor; Table 4) were modified to mimic the lower hinge of IgG4 (L234F)."}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T704","span":{"begin":62,"end":67},"obj":"Protein"},{"id":"T713","span":{"begin":91,"end":101},"obj":"Protein"}],"attributes":[{"id":"A704","pred":"uniprot_id","subj":"T704","obj":"https://www.uniprot.org/uniprot/Q9NZQ7"},{"id":"A705","pred":"uniprot_id","subj":"T704","obj":"https://www.uniprot.org/uniprot/Q9NUZ5"},{"id":"A706","pred":"uniprot_id","subj":"T704","obj":"https://www.uniprot.org/uniprot/Q9EP73"},{"id":"A707","pred":"uniprot_id","subj":"T704","obj":"https://www.uniprot.org/uniprot/Q6WEX4"},{"id":"A708","pred":"uniprot_id","subj":"T704","obj":"https://www.uniprot.org/uniprot/Q66RK1"},{"id":"A709","pred":"uniprot_id","subj":"T704","obj":"https://www.uniprot.org/uniprot/Q2V8D5"},{"id":"A710","pred":"uniprot_id","subj":"T704","obj":"https://www.uniprot.org/uniprot/Q14CJ2"},{"id":"A711","pred":"uniprot_id","subj":"T704","obj":"https://www.uniprot.org/uniprot/B4DU27"},{"id":"A712","pred":"uniprot_id","subj":"T704","obj":"https://www.uniprot.org/uniprot/B2RBA2"},{"id":"A713","pred":"uniprot_id","subj":"T713","obj":"https://www.uniprot.org/uniprot/P51527"},{"id":"A714","pred":"uniprot_id","subj":"T713","obj":"https://www.uniprot.org/uniprot/P51526"}],"text":"The lower hinge amino acids of the IgG1 mAbs durvalumab (anti‐PD‐L1) and anifrolumab (anti‐interferon‐α receptor; Table 4) were modified to mimic the lower hinge of IgG4 (L234F)."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T407","span":{"begin":16,"end":27},"obj":"Body_part"}],"attributes":[{"id":"A407","pred":"fma_id","subj":"T407","obj":"http://purl.org/sig/ont/fma/fma82739"}],"text":"The lower hinge amino acids of the IgG1 mAbs durvalumab (anti‐PD‐L1) and anifrolumab (anti‐interferon‐α receptor; Table 4) were modified to mimic the lower hinge of IgG4 (L234F)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T300","span":{"begin":0,"end":178},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The lower hinge amino acids of the IgG1 mAbs durvalumab (anti‐PD‐L1) and anifrolumab (anti‐interferon‐α receptor; Table 4) were modified to mimic the lower hinge of IgG4 (L234F)."}